<- Go Home
RxSight, Inc.
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Market Cap
$576.6M
Volume
552.4K
Cash and Equivalents
$28.0M
EBITDA
-$33.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$106.6M
Profit Margin
71.87%
52 Week High
$64.50
52 Week Low
$12.53
Dividend
N/A
Price / Book Value
2.06
Price / Earnings
-21.27
Price / Tangible Book Value
2.06
Enterprise Value
$359.3M
Enterprise Value / EBITDA
-11.59
Operating Income
-$36.9M
Return on Equity
11.98%
Return on Assets
-9.29
Cash and Short Term Investments
$229.3M
Debt
$12.0M
Equity
$279.3M
Revenue
$148.3M
Unlevered FCF
-$7.6M
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium